The 36-month beta value for BNTX is at 0.19. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 4 rating it as “overweight,” 7 as “hold,” and 1 as “sell.”
The public float for BNTX is 237.11M, and currently, shorts hold a 1.02% of that float. The average trading volume for BNTX on November 08, 2024 was 971.75K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BNTX) stock’s latest price update
BioNTech SE ADR (NASDAQ: BNTX) has seen a rise in its stock price by 5.89 in relation to its previous close of 107.88. However, the company has experienced a 2.47% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-06 that BioNTech SE’s stock saw a spike in September due to positive data from Summit Therapeutics’ ivonescimab, which has a similar mechanism to BioNTech’s BNT327. BioNTech’s Q3 earnings showed improved revenues and profit, largely driven by its COVID-19 vaccine, Comirnaty, which remains a significant revenue source. Despite the potential in oncology, BNTX’s current valuation is high relative to its non-COVID revenue prospects, warranting a “Hold” rating.
BNTX’s Market Performance
BioNTech SE ADR (BNTX) has experienced a 2.47% rise in stock performance for the past week, with a -3.49% drop in the past month, and a 41.70% rise in the past quarter. The volatility ratio for the week is 4.59%, and the volatility levels for the past 30 days are at 3.08% for BNTX. The simple moving average for the past 20 days is 1.46% for BNTX’s stock, with a 19.88% simple moving average for the past 200 days.
Analysts’ Opinion of BNTX
Morgan Stanley, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $145, previously predicting the price at $93. The rating they have provided for BNTX stocks is “Overweight” according to the report published on September 24th, 2024.
Jefferies gave a rating of “Buy” to BNTX, setting the target price at $150 in the report published on September 17th of the current year.
BNTX Trading at 2.07% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.12% of loss for the given period.
Volatility was left at 3.08%, however, over the last 30 days, the volatility rate increased by 4.59%, as shares sank -5.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.58% upper at present.
During the last 5 trading sessions, BNTX rose by +2.61%, which changed the moving average for the period of 200-days by +18.04% in comparison to the 20-day moving average, which settled at $112.60. In addition, BioNTech SE ADR saw 8.24% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTX starting from ATHOS KG, who proposed sale 8,036 shares at the price of $117.74 back on Oct 16 ’24. After this action, ATHOS KG now owns shares of BioNTech SE ADR, valued at $946,154 using the latest closing price.
ATHOS KG, the 10% Owner of BioNTech SE ADR, proposed sale 25,424 shares at $120.83 during a trade that took place back on Oct 14 ’24, which means that ATHOS KG is holding shares at $3,071,964 based on the most recent closing price.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.64 for the gross margin
The net margin for BioNTech SE ADR stands at -0.19. The total capital return value is set at -0.03. Equity return is now at value -2.37, with -2.07 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 11.73. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -18.57.
Currently, EBITDA for the company is 1.16 billion with net debt to EBITDA at 46.33. When we switch over and look at the enterprise to sales, we see a ratio of 5.62. The receivables turnover for the company is 9.39for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
In conclusion, BioNTech SE ADR (BNTX) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
